Literature DB >> 25207607

The use of opioid analgesics for chronic pain: minimizing the risk for harm.

Charles E Argoff1, Eugene R Viscusi2.   

Abstract

Chronic noncancer pain is common and consequential, affecting ∼100 million people in the United States alone and costing, when direct and indirect costs are combined, in excess of $635 billion. For certain individuals, opioids may be an effective option for the management of chronic pain; however, a series of critical decisions must be made before prescribing opioids to ensure that their potential benefits and possible risks are appropriately and realistically addressed. A thorough history, physical examination, and appropriate testing, including an assessment of risk for substance abuse, misuse, or addiction, should be conducted in patients who are being considered for opioid therapy. Proactively developing a treatment plan that matches the needs and expectations of the patient, while minimizing the potential for substance abuse, is central to the success of pain management. Current standard of care suggests that for most patients, a trial of nonopioid therapies should generally be tried first. There is no single opioid of choice that universally provides the best outcomes for all patients; thus, it is critical for the health-care practitioner to become familiar with the available subclasses, formulations, and modes of administration, and base the treatment plan on clinical experience with the drug, prior patient experience, the availability of the formulation, and cost and coverage. Pain is a dynamic phenomenon in that its characteristics and response to treatment evolve over time, as does the patient's general health state. Both positive and negative changes over time may necessitate a change in medication. Opioids can be prescribed safely and effectively, and when used with appropriate attention to individual patient characteristics may have a positive impact on pain and function. When contemplating initiation of opioid analgesics, clinicians would do well to make it clear to their patient that they will be prescribed on a trial basis with a clear exit strategy for discontinuing such treatment if there is no clear benefit including lack of analgesia, insurmountable adverse effects, and/or frank misuse or abuse of the prescribed drug.

Entities:  

Year:  2014        PMID: 25207607     DOI: 10.1038/ajgsup.2014.3

Source DB:  PubMed          Journal:  Am J Gastroenterol Suppl


  23 in total

1.  Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?

Authors:  Hans G Kress
Journal:  Eur J Pain       Date:  2010-07-24       Impact factor: 3.931

Review 2.  A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs.

Authors:  Charles E Argoff; Daniel I Silvershein
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

3.  The psychological assessment of patients with chronic pain.

Authors:  A H Lebovits
Journal:  Curr Rev Pain       Date:  2000

4.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

5.  Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors.

Authors:  C Chabal; M K Erjavec; L Jacobson; A Mariano; E Chaney
Journal:  Clin J Pain       Date:  1997-06       Impact factor: 3.442

Review 6.  Substance abuse issues in cancer patients. Part 1: Prevalence and diagnosis.

Authors:  S D Passik; R K Portenoy; P L Ricketts
Journal:  Oncology (Williston Park)       Date:  1998-04       Impact factor: 2.990

7.  Universal precautions in pain medicine: a rational approach to the treatment of chronic pain.

Authors:  Douglas L Gourlay; Howard A Heit; Abdulaziz Almahrezi
Journal:  Pain Med       Date:  2005 Mar-Apr       Impact factor: 3.750

8.  A review of abuse-deterrent opioids for chronic nonmalignant pain.

Authors:  Robin Moorman-Li; Carol A Motycka; Lisa D Inge; Jocelyn Myrand Congdon; Susan Hobson; Brian Pokropski
Journal:  P T       Date:  2012-07

9.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

10.  Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.

Authors:  Barbara Donner; Michael Zenz; Michael Tryba; Michael Strumpf
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

View more
  8 in total

Review 1.  Strategies to Identify and Reduce Opioid Misuse Among Patients with Gastrointestinal Disorders: A Systematic Scoping Review.

Authors:  Salva N Balbale; Itishree Trivedi; Linda C O'Dwyer; Megan C McHugh; Charlesnika T Evans; Neil Jordan; Laurie A Keefer
Journal:  Dig Dis Sci       Date:  2017-08-05       Impact factor: 3.199

Review 2.  Pharmacotherapies in Geriatric Chronic Pain Management.

Authors:  Zachary A Marcum; Nakia A Duncan; Una E Makris
Journal:  Clin Geriatr Med       Date:  2016-11       Impact factor: 3.076

3.  The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain.

Authors:  Howard B Cotler; Roberta T Chow; Michael R Hamblin; James Carroll
Journal:  MOJ Orthop Rheumatol       Date:  2015-06-09

4.  Mindfulness-based stress reduction (MBSR) as sole intervention for non-somatisation chronic non-cancer pain (CNCP): protocol for a systematic review and meta-analysis of randomised controlled trials.

Authors:  Lawrence Leung; Han Han; Mary Martin; Jyoti Kotecha
Journal:  BMJ Open       Date:  2015-05-18       Impact factor: 2.692

5.  The application of nalbuphine in patient-controlled intravenous analgesia for patients undergoing subtotal gastrectomy.

Authors:  Li Yang; Jinjing Wu; Tao Li
Journal:  Exp Ther Med       Date:  2017-12-14       Impact factor: 2.447

6.  Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders.

Authors:  Chang Ju Hwang; Sung Soo Chung; Kyu-Yeol Lee; Jae Hyup Lee; Seong-Hwan Moon; Jin-Hyok Kim; Kyu-Jung Cho; Jae-Sung Ahn; Dong-Soo Kim; Ye-Soo Park; Hye-Jeong Park
Journal:  Clin Orthop Surg       Date:  2018-02-27

7.  Sedative, analgesic, behavioral and clinical effects of intravenous nalbuphine-xylazine combination in camels (Camelus dromedarius).

Authors:  Ahmed H Khalil; Atef S Abd Al-Galil; Ahmed A Sabek; Mohamed M Zeineldin; Seham Y Abo-Kora
Journal:  J Vet Sci       Date:  2019-09       Impact factor: 1.672

8.  Chemoenzymatic Synthesis of Optically Active Ethereal Analog of iso-Moramide-A Novel Potentially Powerful Analgesic †.

Authors:  Paweł Borowiecki
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.